RenaissThera Closes Seed Funding Round

Funding Rounds

▤ Summary

RenaissThera, a Bengaluru, India-based biotechnology company for cardio-metabolic diseases, raised an undisclosed amount in Seed funding. The company intends to use the funds to accelerate the development of novel small-molecule therapies targeting GLP-1 and GIP receptors for Cardio-metabolic (CM) diseases, with an emphasis on diabetes and obesity. Led by CEO Dr. Ramkesh Meena, RenaissThera is a biotechnology company dedicated to developing new small-molecule targeted therapies leveraging AI platforms. It focuses on high-unmet-need areas of prevalent diseases in key therapy areas such as Cardio-metabolic including diabetes and obesity indications leveraging its platform empowered by GenAI tools.

$ Funding

$
Amount - Total raised
□
Date December 10, 2024 Announcement date
◎
Investors - Lead investors
▥
Company - Funded company

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies